Has Jacquelyn Smith, MD received payments from drug or device companies?

Yes. Drug and device makers reported $62,812 in general payments to Jacquelyn Smith, MD across 828 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jacquelyn Smith, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jacquelyn Smith, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jacquelyn Smith, MD

Rheumatology · Louisville, KYNPI 1154769131

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (42.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 74.3% of it on its own, with 29 other manufacturers making up the rest. Among rheumatology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,812in general payments, 2019–2025

Across 828 payments — averaging $75.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$47K
Amgen$4K
Johnson & Johnson$3K
AbbVie$2K
UCB, Inc.$1K
Novartis$1K
plus $4K from 24 others

What the payments were for

Consulting fees$13,83522%
Speaking & faculty fees$26,71043%
Travel & lodging$6,02810%
Food & beverage$16,21226%
Education$270%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	84	$46,643
Amgen(2 entities)	193	$4,469
Johnson & Johnson	88	$2,873
AbbVie	119	$2,202
UCB, Inc.	77	$1,305
Novartis	43	$1,015
AstraZeneca(2 entities)	36	$714
Mallinckrodt Hospital Products Inc.	23	$581
Pfizer	34	$531
E.r. Squibb & Sons, L.L.C.	36	$479
GSK	21	$363
Lilly USA, LLC	12	$215
Sanofi	7	$191
Aurinia Pharma U.S., Inc.	9	$153
Radius Health, Inc.	8	$140
Bayer	1	$123
Regeneron Healthcare Solutions, Inc.	6	$116
Janssen Scientific Affairs, LLC	1	$111
Bristol Myers Squibb	3	$111
Sobi, Inc	6	$109
Genentech USA, Inc.	5	$103
Organon	5	$67
ANI Pharmaceuticals, Inc.	2	$33
Mallinckrodt Enterprises LLC	2	$33
Actelion Pharmaceuticals US, Inc.	1	$33
United Therapeutics Corporation	1	$27
Merck	2	$25
Antares Pharma, Inc.	1	$18
Pacira Therapeutics, Inc.	1	$17
Ferring Pharmaceuticals Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OFEV$15,203
KRYSTEXXA$1,608
SIMPONI ARIA$1,358
Adempas$123
Cimzia$120
Tremfya$111
STELARA$111

How this compares

$62,812 in reported general payments places this provider in the 95th percentile of 81 rheumatology providers in Kentucky.

See all rheumatology providers in Kentucky →

Medicare billing

Part B allowed, 2024

$928,416

Medicare patients

380

Services billed

92,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Actemra ActpenTocilizumab	11	$37,697
Hydroxychloroquine Sulfate	238	$6,079
Leflunomide	42	$2,866
MethotrexateMethotrexate Sodium	119	$2,677
Celecoxib	24	$1,330
Prednisone	198	$995
Azathioprine	14	$455
Allopurinol	30	$302
Methylprednisolone	18	$124
Folic Acid	13	$96

Paid to pharmacies, not to this prescriber.

Other rheumatology in Louisville

Gary CrumpLouisville$176K
Benjamin BooneLouisville$80K
Lisa JuneLouisville$27K
Housam SarakbiLouisville$27K
Carolyn GleasonLouisville$25K
Janet LeonLouisville$20K
Steven SternLouisville$3K
Heidi RogersLouisville$2K
Mohamed JallohLouisville$2K
Ami JoglekarLouisville$830

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →